Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Partnering with University of … 29 COVID-19-related actions - Healthcare Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS Published May 5, 2020 8:00AM EDT Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS - read this article along with other careers information, tips and advice on BioSpace Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program PRESS RELEASE GlobeNewswire May. Diffusion Pharmaceuticals Inc. SEC Filing - Proxy Statement (definitive) (DEF 14A) April 29, 2020 SEC Filings • Wed, Apr. The MarketWatch News Department was not involved in the creation of this content. About Diffusion Pharmaceuticals Inc. ... of the Company’s emergency medical services providers, enrollment in this trial is expected to be minimal until the COVID … Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 PatientsPartnering with University of Virginia Health and iTHRIV - read this article along with other careers information, tips and advice on BioSpace Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute … 27, 2020 at 8:25 a.m. Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19 Apr. 26, 2020, 02:00 PM ET on GlobeNewswire Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases